Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes

Noriyoshi Iriyama, Yoshihiro Hatta & Masami Takei
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

Abstract

It has been shown that an increase in cytotoxic lymphocyte counts in the peripheral blood occurs rapidly after taking dasatinib, but the underlying mechanism is not yet elucidated. To investigate the influence of dasatinib on signal transduction pathways, we investigated the changes in JAK-STAT, mitogen-activated protein kinase (MAPK), and AKT in cytotoxic lymphocytes, including natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), before and after dasatinib treatment in chronic myeloid leukemia patients. Among a total of 30 patients, 18 were treated with dasatinib, nine with imatinib, and three with nilotinib. At constitutive levels, the expression of phosphorylated proteins, pSTAT1, pSTAT3, and pERK in NK cells and pSTAT3 in CTLs, was significantly higher in dasatinib-treated patients. Among the patients evaluated, only dasatinib-treated patients showed inhibition of multiple signaling pathways after taking a tyrosine kinase inhibitor. The magnitude of pERK and pAKT inhibition was closely associated with an increase in NK cells and CTLs, respectively, after taking a tyrosine kinase inhibitor. Those responses were more evident in patients with cytomegalovirus IgG positivity. In this study, we demonstrated for the first time, the influence of dasatinib on cell events in cytotoxic lymphocytes in vivo and explained the possible underlying mechanism that results in lymphocyte mobilization after dasatinib treatment.
indicating a rapid mobilization of pooled lymphocytes [12, 14]. Although substantial evidence demonstrating the contribution of immune activation involving NK cells and cytotoxic T lymphocytes (CTLs) on dasatinib treatment has accumulated, there has been no research explaining the mechanism underlying the rapid response to dasatinib in vivo. It is well known that the activity, adhesion, and migration of lymphocytes are regulated through changes in multiple signal transduction pathways such as the mitogen-activated protein kinase (MAPK) and AKT pathways [15, 16]. When the speed of response is considered, the changes in signal transduction pathways not involving protein synthesis or protein degradation are assumed to be critical regulation systems for rapid mobilization of cytotoxic lymphocytes. However, samples procured from patients are complex, and therefore, the evaluation of changes in cell signaling limited to specific subpopulations such as NK cells or CTLs is difficult when conventional methods such as western blots are used.

Phospho-flow, a unique method that enables the sensitive and quantitative detection of phosphorylated proteins at the single-cell level, was developed by the Nolan group recently [17, 18]. This method is able to evaluate cell signaling in each lymphocyte type, because total nuclear cells can be separated by costaining with antibodies for their surface markers. Given the lack of detailed data regarding the effect of dasatinib on the normal immune system, we applied the phospho-flow method to perform a comprehensive evaluation of the changes in signal transduction pathways in lymphocytes of CML patients during TKI treatment. Furthermore, the association between the change in the expression of phosphorylated proteins and the NK cell or CTL mobilization was investigated. Herein, we describe how dasatinib may influence cell signaling in cytotoxic lymphocytes and describe the possible mechanism that results in the activation and mobilization of cytotoxic lymphocytes.

**Patients and Methods**

**Patients and treatment**

This study included well-controlled CML patients in the chronic phase, who scored less than 1% of the International Scale (IS) (to avoid the effect of concomitant mononuclear cells derived from the CML clone) and who were treated for more than 3 months with any TKI, because protein phosphorylation and response to cytokines in immune cells are impaired at the diagnostic stage [19]. Patients who were taking any cytotoxic agent or immunosuppressant (e.g., corticosteroid), had chronic inflammatory disease, or who had received allogeneic hematopoietic transplantation were excluded from the analysis. The background of the patients in the study was primarily immunocompetent with little or no effect of the underlying disease. The study was approved by the research ethics board of Nihon University Itabashi Hospital (identifier: RK-150609-15), and the study was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent prior to study enrollment.

**Assessment of treatment response and molecular analyses**

Quantification of the BCR-ABL1 transcript by real-time quantitative polymerase chain reaction analysis was performed to assess the molecular response. BCR-ABL1 transcript analysis was performed by Special Reference Laboratories (SRL; Tokyo, Japan). A major molecular response (MMR) was defined as ≤0.1% and a deep molecular response (DMR) was ≤0.0032% of the IS.

**Reagents**

Dasatinib was purchased from BioVision (Mountain View, CA) and dissolved in dimethyl sulfoxide (DMSO) at a concentration of 300 μmol/L. Imatinib and nilotinib were purchased from Tokyo Chemical Industry (Tokyo, Japan) and ChemScene (Monmouth Junction, NJ) and dissolved in DMSO at a concentration of 2 mmol/L, respectively. Antibodies for immunophenotyping, including phycoerythrin (PE)-conjugated anti-CD56 IgG, PC5-conjugated anti-CD8 IgG, PC7-conjugated anti-CD3 IgG, and each isotype control IgG were purchased from Beckman Coulter (Brea, CA). Fluorescein isothiocyanate (FITC)-labeled polyclonal rabbit IgG antibodies for phosphorylated proteins, including pJAK1 (Y1034, #3238R), pJAK2 (Y1007, #2485R), pSTAT1 (Y701, #1657R), pSTAT3 (Y705, #1658R), pERK (T202/Y204, #4690R), pJNK (T183/Y185, #4668R), pp38 (T180/Y182, #9212R), pAKT (Y310, #4690R), and isotype control (#0295P) were purchased from Bioss (Wobun, MA, USA).

**Sample collection**

Peripheral blood samples were collected before and after TKI intake. Sample collection after TKI dosage was performed 1 h after dasatinib treatment or 2 h after imatinib or nilotinib treatment, which is considered the peak concentration time as described previously [12]. Complete blood cell counts and the percentage of each leukocyte subset were evaluated in all samples. For analysis of signal transduction pathways using the phospho-flow method, mononuclear cell fractions were isolated from freshly collected peripheral blood using Lymphoprep™ (Cosmo Bio
Co., Ltd., Tokyo, Japan) to classify each cellular subset precisely by reducing the effect of outliers.

**Cell culture**

Mononuclear cells obtained from patient blood samples were cultured in a RPMI-1640 medium (Gibco-BRL, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco-BRL) and antibiotics [100 U/ml penicillin and 100 μg/ml streptomycin (Gibco-BRL)] at 37°C in a humidified atmosphere (5% CO2 in air) with 100 nmol/L and 300 nmol/L dasatinib, 2 μmol/L imatinib, and 2 μmol/L nilotinib, for 60 min. DMSO was used as a control vehicle.

**Phospho-flow method**

Mononuclear cells isolated from patient peripheral blood samples were fixed with 1.5% paraformaldehyde (PFA) at room temperature for 10 min and were permeabilized with 90% ice-cold methanol at −20°C overnight. For analysis of phosphorylated proteins in combination with surface antigen staining, we first washed the cells twice with phosphate-buffered saline (PBS) containing 2.5% FBS and 0.5% NaN3 (PBSF) and then stained them with surface antibodies including CD3, CD8, and CD56 at room temperature for 15 min in the dark. Cells stained with antibodies were divided and stained with each phospho-specific antibody at a concentration of 10 μg/mL at room temperature for 30 min in the dark. After staining, cells were rewashed with PBSF and analyzed by flow cytometer (FC500, Beckman Coulter). The absolute lymphocyte count was expressed using the total blood cell count and the percentage of lymphocytes. Lymphocytes were classified according to the immunophenotypes determined by flow cytometry. The lymphocyte fraction was gated with forward and side scatter, and double-gating analyses were performed with CD3+CD8 and CD3+CD56. The lineages of CTLs were defined according to expression of CD3+ CD8+ and NK cells with CD3-CD56+. The absolute values of individual lymphocyte subsets were expressed as the total lymphocyte count multiplied by the percentage of each lymphocyte subset. We found that the fixation/permeabilization step had little or no effect on the probability of each lymphocyte fraction. For evaluation of phospho-specific proteins, NK cell and CTL fractions were gated separately and the expression level of each protein in the cells specified was denoted as “median” fluorescence intensity (MFI), as is recommended for the assessment of blood samples [18]. The changes in MFI values are presented as log2 (fold change [FC]). The Flow-Check™ system (Beckman Coulter) was used for ensuring the quality of values obtained in daily analyses.

**Statistical analysis**

The Mann–Whitney U and ANOVA tests were used to determine statistical significance in each group as appropriate. The correlation between factors was evaluated with the Pearson correlation coefficient. P < 0.05 was considered to be significant. Statistical analyses were performed using JMP software, version 11.0.0 (SAS Institute Inc., Cary, NC).

**Results**

**Patient characteristics**

In total, 30 patients with CML in CP were enrolled in this study. Patient characteristics are presented in Table 1. Of 30 patients, 18 were treated with dasatinib (11 first-line, seven second-line or later), nine with first-line imatinib, and three with first-line nilotinib. CMV IgG was evaluated only in the dasatinib-treated patients, with a positive result in 13 patients. Regarding the treatment response, 11 patients were in MMR and 17 in DMR. Data after TKI dosage were ineligible in two patients (no. 16 and 30). The representative data of histograms using the phospho-flow method are shown in Figure 1. Lymphocyte fractions were classified according to surface antibodies including CD3, CD8, and CD56 (Fig. 1A). Cells were costained with phospho-specific antibodies and the histograms of phosphorylated proteins in NK cell fraction were denoted and expressed as MFI in Figure 1B.

**Mobilization of cytotoxic lymphocytes after TKI intake**

Initially, we determined whether or not cytotoxic lymphocytes were mobilized rapidly after taking dasatinib but not imatinib or nilotinib in the study population. The changes in the absolute values of lymphocytes, NK cells, and CTLs are shown in Figure 2. The number of total lymphocytes, NK cells, or CTLs after dasatinib intake was higher compared to the number before dasatinib intake and the number after taking other TKIs (Fig. 2A). However, the number of total lymphocytes, NK cells, and CTLs before dasatinib intake did not differ statistically from those before intake of other TKIs (Fig. 2A). Furthermore, morphological large granular lymphocytosis was not observed in the blood samples taken before dasatinib intake (data not shown). The relative increase in total lymphocytes, NK cells, or CTLs was apparent only in patients treated with dasatinib, with significant differences compared to those treated with other TKIs (Fig. 2B). Thus, our study population clearly reproduced the rapid lymphocyte mobilization after taking dasatinib, but not imatinib or nilotinib [12].
Constitutive activities of signal transduction pathways in NK cells and CTLs

We investigated the constitutive levels of phosphorylated proteins in NK cells and CTLs, as shown in Figure 1B. All phosphorylated proteins were detectable and their levels were similar in NK cells and CTLs. With regard to the values obtained, the levels of pSTAT1, pSTAT3, and pAKT in NK cells and pSTAT3 in CTLs before taking TKI were significantly higher in dasatinib-treated patients than in imatinib- or nilotinib-treated patients (Fig. 3A and B). Thus, the expression levels of some phosphorylated proteins were higher in patients on dasatinib treatment. However, levels of MAPKs, including pERK, pJNK, and pp38, did not differ between groups.

Change of signal transduction pathways in cytotoxic lymphocytes

Following treatment with TKIs, the change in transduction pathways was analyzed by separating NK cells and CTLs. Results for the 28 available patients (17 dasatinib, nine imatinib, and two nilotinib) are shown in Figure 4. A heat map analysis demonstrated inhibition of signal transduction pathways primarily in dasatinib-treated patients (no. 1–15, 17, 18) but not in imatinib- or nilotinib-treated (no. 19–29) patients, suggesting that inhibition of signal transduction pathways is the major event occurring in dasatinib-treated patients. This phenomenon was common to NK cells and CTLs after consumption of dasatinib, but the detailed profiles slightly differed in each patient (Fig. 4A and B). Other factors such as treatment term, age, sex, and treatment line were not associated with a change in cell signaling.

Correlations between changes in phosphorylated protein levels and mobilization of cytotoxic lymphocytes

Next, we investigated whether or not inhibition of phosphorylated proteins was correlated with lymphocyte

| Patient no. | Sex | Age | Treatment       | Dose (mg/day) | Response | PE | CMV IgG |
|------------|-----|-----|-----------------|---------------|----------|----|---------|
| 1          | F   | 79  | Dasatinib, first-line | 50            | DMR      | Yes| Positive|
| 2          | F   | 74  | Dasatinib, first-line | 100           | MMR      | No | Positive|
| 3          | F   | 34  | Dasatinib, first-line | 100           | No MMR   | No | Negative|
| 4          | F   | 62  | Dasatinib, second-line | 100           | DMR      | Yes| Positive|
| 5          | F   | 31  | Dasatinib, second-line | 100           | MMR      | No | Positive|
| 6          | F   | 66  | Dasatinib, second-line | 100           | DMR      | No | Positive|
| 7          | M   | 27  | Dasatinib, first-line | 100           | DMR      | No | Negative|
| 8          | M   | 25  | Dasatinib, first-line | 100           | MMR      | No | Positive|
| 9          | M   | 64  | Dasatinib, first-line | 100           | DMR      | Yes| Positive|
| 10         | M   | 56  | Dasatinib, first-line | 50            | DMR      | Yes| Positive|
| 11         | M   | 33  | Dasatinib, first-line | 100           | DMR      | No | Positive|
| 12         | M   | 71  | Dasatinib, first-line | 50            | DMR      | Yes| Positive|
| 13         | M   | 25  | Dasatinib, first-line | 100           | MMR      | No | Negative|
| 14         | M   | 30  | Dasatinib, first-line | 100           | MMR      | No | Negative|
| 15         | M   | 34  | Dasatinib, second-line | 100           | MMR      | No | Positive|
| 16         | M   | 47  | Dasatinib, third-line | 50            | No MMR   | No | Positive|
| 17         | M   | 85  | Dasatinib, second-line | 50            | MMR      | Yes| Positive|
| 18         | M   | 30  | Dasatinib, second-line | 100           | MMR      | No | Negative|
| 19         | F   | 38  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 20         | F   | 71  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 21         | F   | 43  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 22         | F   | 63  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 23         | F   | 51  | Imatinib, first-line | 200           | DMR      | No | NA      |
| 24         | F   | 58  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 25         | M   | 68  | Imatinib, first-line | 300           | MMR      | No | NA      |
| 26         | M   | 54  | Imatinib, first-line | 400           | DMR      | No | NA      |
| 27         | M   | 45  | Imatinib, first-line | 400           | MMR      | No | NA      |
| 28         | M   | 72  | Nilotinib, first-line | 600           | MMR      | No | NA      |
| 29         | M   | 49  | Nilotinib, first-line | 600           | DMR      | No | NA      |
| 30         | M   | 84  | Nilotinib, first-line | 600           | DMR      | No | NA      |

PE, pleural effusion; CMV, cytomegalovirus; MMR, major molecular response; DMR, deep molecular response; NA, not available.
mobilization. As shown in Figure 5, the relative increase in NK cell counts was closely correlated with the magnitude of STAT1, pERK, pJNK, pp38, and pAKT inhibition in NK cell fractions (Fig. 5A). Similarly, the relative increase in CTL counts was also closely correlated with the magnitude of pERK and pAKT inhibition in CTL fractions, suggesting that changes in the expression of the pERK and pAKT pathways are critical for regulating cytotoxic lymphocyte mobilization in both NK cells and CTLs (Fig. 5B).

Figure 1. Flow cytometric analysis of each lymphocyte subset and expression of phosphorylated proteins. Representative data are shown. Lymphocyte fractions are classified according to surface antibodies including CD3, CD8, and CD56. Natural killer (NK) cells were defined as the CD3-CD56+ immunophenotype and cytotoxic T lymphocytes (CTLs) were CD3+CD8+ (A). Cells were costained with phospho-specific antibodies, including antibodies targeting pJAK1, pJAK2, pSTAT1, pSTAT3, pERK, pJNK, pp38, and pAKT, and expression levels of the isotype control and phosphorylated proteins in NK cells are presented (B). The values for the isotype control and each phosphorylated protein are shown as the median fluorescence intensity (MFI).

Figure 2. Changes in the number of lymphocytes, natural killer (NK) cells, and cytotoxic T lymphocytes (CTL) are shown. The values were compared before and after treatment (1 h for dasatinib and 2 h for imatinib or nilotinib) or according to treatment (A). The relative changes in the number of lymphocytes, NK cells, and CTLs are also shown and are expressed as log2 (fold change [FC]) (B).
Dasatinib directly induces changes in pERK and pAKT

It is assumed that lymphocyte mobilization might be involved in the changes in the expression of phosphorylated proteins described above, because differences in phosphorylated protein levels between the mobilized lymphocytes and those already existing in the circulation cannot be measured. In this regard,
representative histograms for pERK or pAKT expression before and after dasatinib treatment are shown in Figure 6. A significant inhibition of pERK and pAKT in NK cells after dasatinib intake was observed and the increase in the number of NK cells was a result of lymphocyte mobilization. This finding suggests that the expression of phosphorylated proteins in cytotoxic lymphocytes mobilized by dasatinib from the tissue in which lymphocytes were pooled was almost the same as that in circulating cytotoxic lymphocytes exposed to dasatinib. Moreover, we performed an in vitro study to test whether or not dasatinib directly influences phosphorylated proteins, including pERK and pAKT, in cytotoxic lymphocytes. Mononuclear cells were obtained from patients before taking dasatinib who had lymphocyte mobilization. The cells were incubated with 100 nmol/L or 300 nmol/L dasatinib, 2 μmol/L imatinib, 2 μmol/L nilotinib, or DMSO vehicle for 1 h, fixed with PFA, permeabilized with methanol, stained with each

Figure 5. Correlations between changes in cell number and changes in the expression levels of each phosphorylated protein in natural killer (NK) cell and cytotoxic T lymphocyte (CTL) fractions (n = 28). Values are shown as log2 (fold change [FC]).

Figure 6. Representative histograms showing expression changes of pERK (A) and pAKT (B) in the natural killer (NK) cell fraction.
antibody (surface antibodies and antibodies against pERK and pAKT) and evaluated by flow cytometry \((n = 5)\). The results are shown in Figure 7. Dasatinib treatment reduced the expression of pERK and pAKT in both NK cells and CTLs with significant differences at a concentration of 300 nmol/L compared to the DMSO control. No significant apoptotic effect was observed in lymphocytes treated with 300 nmol/L dasatinib by trypan blue exclusion assay (data not shown). Thus, pERK and pAKT inhibition results from a direct effect on cytotoxic lymphocytes. However, nilotinib also significantly inhibited pERK expression (but not pAKT) in both NK cells and CTLs.

**Association between the incidence of pleural effusion (PE) and pERK or pAKT inhibition**

The major adverse event associated with dasatinib treatment was the incidence of PE, which occurred in six patients (Table 1). With respect to the association of incidence of PE, there were no differences in the levels of pERK and pAKT in NK cells and CTLs. However, all but one PE-positive patient had a reduced dasatinib dose (50 mg) at the time of sample collection, possibly resulting in an underestimation of the response to dasatinib (data not shown).

**Association of CMV IgG status with pERK and pAKT inhibition**

Finally, we analyzed the association between CMV IgG status and pERK or pAKT inhibition after dasatinib intake to clarify whether or not the factors identified were linked to prior CMV infection status. As shown in Figure 8, the effects of pERK or pAKT inhibition on both NK cell and CTL counts were relatively low in CMV IgG-negative, dasatinib-treated patients and were similar to those in patients treated with other TKI. Thus, the sensitivity to dasatinib in cytotoxic lymphocytes is more profound in CMV IgG-positive patients.

**Discussion**

A change in signal transduction pathways by TKIs is a major event that influences the incidence of adverse events as well as treatment efficacy in patients. Lymphocytosis is observed in 27–73% of patients under dasatinib treatment and is associated not only with the development of PE, colitis, and autoimmune-like symptoms but also with favorable outcomes [7–9, 20]. Evidence for the importance of lymphocytosis has accumulated, but the cell signaling events involved in specific phenomena have not yet been elucidated. In this study, we identified for the first time, the cell signaling events for cytotoxic lymphocytes in CML patients treated with dasatinib.

Our study demonstrated that pERK and pAKT expression was significantly reduced in dasatinib-treated patients compared to imatinib- and nilotinib-treated patients and dasatinib’s inhibitory effect on them was closely associated with the mobilization of cytotoxic lymphocytes, but this effect seemed to be linked to a prior history of CMV infection. Further study is required to determine the target molecule affected by dasatinib in patients with CMV IgG positivity. In addition, our in vitro study showed that...
inhibitory effects on phosphorylated proteins, including 
pERK and pAKT, were more apparent upon treatment 
with 300 nmol/L dasatinib than with 100 nmol/L, sup-
porting the fact that the incidence of lymphocytosis depends 
on drug concentration. Because lymphocytosis actually 
occurs at concentrations less than 300 nmol/L [12], we 
assumed that dasatinib might rapidly distribute into tis-
sues where lymphocytes are pooled at higher concentra-
tions than in circulation. Indeed, it has been shown in 
rat that dasatinib concentration in tissues (such as the 
lung and liver) was clearly higher than that in circulation 
after 1 h of exposure to dasatinib [21].

Although association with a Th1 response is assumed 
in dasatinib-treated patients as suggested by the predomi-
nant expression of interferon-γ in T-cells [22], the rapid 
mobilization in cytotoxic lymphocytes is likely not cytokine-
dependent because of the lack of evidence of cytokine 
secretion after dasatinib intake [12]. However, higher levels 
of pSTAT1 and/or pSTAT3 at constitutive levels in 
dasatinib-treated patients might partially result from a 
Th1 response. In contrast to our study results, a previous 
study by Jalkansen et al. [19] showed that dasatinib inhibits 
the level of pSTAT3 in nonmalignant cells. Because our 
study result showed a transient inhibition of pSTAT3 after 
dasatinib intake in cytotoxic lymphocytes, the discrep-
ancy was considered to be due to the timing of sample 
collection. Furthermore, there may be some differences among 
TKIs in relation to treatment response and the change in 
the signal transduction pathways. Jalkanen et al. [23] 
analyzed other signal transduction pathways in mononu-
clear cells derived from the bone marrow in imatinib-
treated patients and reported that patients who achieved 
optimal treatment response showed lower expression level 
of pSTAT5b or phospholipase C-γ. On the other hand, 
patients treated with dasatinib showed higher levels of 
pERK and pAKT than those in the patients treated with 
other TKIs, suggesting the rationale that activated signal 
transduction pathways are associated with the induction 
of immune-mediated mechanisms. The association of treat-
ment response to dasatinib and pERK or pAKT expression 
at a constitutive level should be investigated in larger-scale 
studies.

A transient increase in malignant cells in the circulation 
in patients with chronic lymphocytic leukemia (CLL) was 
observed after treatment with Bruton’s tyrosine kinase 
(BTK) inhibitor ibrutinib or phosphoinositide 3-kinase 
(PI3K) inhibitor idelalisib [24, 25], similar to the lym-
phocytosis in dasatinib-treated patients. BTK and PI3K 
are essential pathways associated with the mechanism 
underlying the development and progression of CLL [26, 
27]. Pharmacologic inhibition of these pathways inhibits 
downstream pathways, including pERK or pAKT, which 
are major regulators for integrin expression [15, 16]. The 
underlying mechanism for CLL cell expansion is believed
to be the loss of potency to adhere to the microenvironment through cell signaling inhibition. This phenomenon observed in CLL patients supports our finding about inhibitory effects for integrin via signal transduction pathways linked to the mobilization of cytotoxic lymphocytes. Although there is little margin for integrin degradation when the half-life of integrin molecules is taken into account (approximately 18 h) [28], a direct effect of dasatinib on signal transduction pathways could explain the mechanism underlying the rapid mobilization of lymphocytes, which occurs within 1 h. Integrin heterodimers are constantly internalized from the cell membrane to endosomal compartments in the processes of cell adhesion and migration [29]. This traffic system, the so-called integrin recycling system, has a shorter turnaround time (around 30 min) [30], and integrin recycling from the endosome to the cell surface membrane is positively regulated by ERK and AKT activity [15, 16, 29, 31]. In particular, integrin αβ1, αβ3, and α6β4 are regulated by the AKT/GSK-3β pathway [29]. Collectively, the expression of integrin on membrane surface could be reduced within 1 h owing to delayed integrin turnover by pERK and/or pAKT inhibition. Therefore, we believe that suppression of the integrin recycling system through the inhibition of pERK and/or pAKT pathways is a key mechanism that enables mobilization of cytotoxic lymphocytes.

However, some evidence has suggested that the proliferated NK cells show a differentiated immunophenotype, and their cytotoxicity is more potent than that of cells not exposed to dasatinib. It is therefore natural to wonder whether inhibition of the signal transduction pathways associated with dasatinib may suppress immune function. Previous reports have shown that lymphocyte expansion is associated with CMV-associated infection or reactivation [13], but other studies have not [32]. This discrepancy may result from differences in the baseline characteristics of the patients investigated. Dasatinib treatment would influence the incidence of infectious complications if used in patients with less active immune function. Furthermore, suppression of immune function in vitro studies is believed to result from maintenance of a consistent dasatinib concentration, as the pharmacokinetics are considerably different from those in vivo [33–35]. In our study, remarkable infectious complications were not observed, probably because of immunocompetence and well-controlled disease status in the patients analyzed. The constitutive levels in signal transduction pathways investigated in dasatinib-treated patients were almost the same as or higher than those in patients treated with other TKIs. Taking these results, the treatment schedule (once daily), and a shorter half-life of dasatinib in the blood into account, pERK or pAKT inhibition is transient, and these kinases are reactivated within a short period of time. Therefore, the expression of these phosphorylated proteins in cytotoxic lymphocytes dramatically and dynamically fluctuates with dasatinib treatment. Based on these findings, we assumed that the effect of dasatinib, similar to pulse therapy, induced an immune response through transient and repeated cell signal inhibition. Interestingly, a previous in vitro study by Hassold et al. [36] demonstrated that NK cells treated with dasatinib showed a reduced effector function but their cytotoxicity was potentiated after washout of dasatinib, supporting our notion that reactivation of those signal transduction pathways along with decreased drug concentration leads to the potentiation of immune function. Collectively, we propose that the response to dasatinib indicated by rapid mobilization of cytotoxic lymphocytes is a result of transient inhibition of signal transduction pathways in the immune system, but the prevalence of the signal response confers the activation of tumor immunity.

In conclusion, our data demonstrating changes in signal transduction pathways in cytotoxic lymphocytes using the phospo-flow method offer novel insights into the mechanisms underlying dasatinib-induced cytotoxic lymphocyte mobilization and activation of immune function, which may be highly advantageous because of the potential eradication of minimal residual disease.

Acknowledgments

We thank all participants who made this research possible. We also thank Eiko Ishizuka for technical support and Hideo Araki for sample collection.

Conflicts of Interest

NI and YH received honoraria and speaker fees from Bristol-Myers Squibb and Novartis. MT reports research funds from Bristol-Myers Squibb and Novartis.

References

1. O’Brien, S. G., F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348:994–1004.

2. Kantarjian, H., S. O’Brien, E. Jabbour, J. Shan, F. Ravandi, T. Kadia, et al. 2011. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J. Clin. Oncol. 29:3173–3178.

3. Tauchi, T., M. Kizaki, S. Okamoto, H. Tanaka, M. Tanimoto, K. Inokuchi, et al. 2011. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous...
leukemia by the TARGET system. Leuk. Res. 35:585–590.

4. Yanada, M., J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, et al. 2006. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24:460–466.

5. Jabbour, E., H. M. Kantarjian, G. Saglio, J. L. Steegmann, N. P. Shah, C. Boqué, et al. 2014. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494–500.

6. Ravandi, F., S. O’Brian, D. Thomas, S. Faderl, D. Jones, R. Garris, et al. 2010. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116:2070–2077.

7. Mustjoki, S., M. Ekblom, T. P. Arstila, I. Dybedal, P. K. Epling-Burnette, F. Guilhot, et al. 2009. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398–1405.

8. Kim, D. H., S. Kamel-Reid, H. Chang, R. Sutherland, C. H. Jung, H.-J. Kim, et al. 2009. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135–139.

9. Kumagai, T., E. Matsuki, K. Inokuchi, K. Ohashi, A. Shimagawa, J. Takeuchi, et al. 2014. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int. J. Hematol. 99:41–52.

10. Iriyama, N., S. Fujisawa, C. Yoshida, H. Wakita, S. Chiba, S. Okamoto, et al. 2015. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am. J. Hematol. 90:819–824.

11. Nagata, Y., K. Ohashi, S. Fukuda, N. Kamata, H. Akiyama, and H. Sakamaki. 2010. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int. J. Hematol. 91:799–807.

12. Mustjoki, S., K. Auvinen, A. Kreutzman, P. Rousselot, S. Hernesniemi, T. Melo, et al. 2013. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914–924.

13. Kreutzman, A., K. Ladell, C. Koechel, E. Gostick, M. Ekblom, L. Stenke, et al. 2011. Expansion of highly differentiated CD8 + T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587–1597.

14. Imagawa, J., H. Tanaka, K. Matsumoto, K. Morita, Y. Harada, and H. Harada. 2012. A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int. J. Hematol. 96:194–199.

15. Moreno-Layeca, P., and C. H. Streuli. 2014. Signalling pathways linking integrins with cell cycle progression. Matrix Biol. 34:144–153.

16. Juliano, R. L., P. Reddig, S. Alahari, M. Edin, A. Howe, and A. Aplin. 2004. Integrin regulation of cell signalling and motility. Biochem. Soc. Trans. 32:443–446.

17. Krutzik, P. O., and G. P. Nolan. 2003. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry Part A 55:61–70.

18. Krutzik, P. O., A. Trejo, K. R. Schulz, and G. P. Nolan. 2011. Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples. Methods Mol. Biol. 699:179–202.

19. Jalkanen, S. E., J. Vakkila, A. Kreutzman, J. K. Nieminen, K. Porkka, and S. Mustjoki. 2011. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. Exp. Hematol. 39:102–113.

20. Qiu, Z.-Y., W. Xu, and J.-Y. Li. 2014. Large granular lymphocytosis during dasatinib therapy. Cancer Biol. Ther. 15:247–255.

21. He, K., M. W. Lago, R. A. Iyer, W. C. Shyu, W. G. Humphreys, and L. J. Christopher. 2008. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab. Dispos. 36:2564–2570.

22. Kreutzman, A., M. Ilander, K. Porkka, J. Vakkila, and S. Mustjoki. 2014. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 3:e28925.

23. Jalkanen, S. E., A. M. Lahesmaa-Korpinnen, C. A. Heckman, V. Rantanen, K. Porkka, S. Hautaniemi, et al. 2012. Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Exp. Hematol. 40:705–714.

24. Herman, S. E. M., C. U. Niemann, M. Farooqui, I. Jones, R. Z. Mustafa, A. Lipsky, et al. 2014. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28:2188–2196.

25. Brown, J. R., J. C. Byrd, S. E. Coutre, D. M. Benson, I. W. Flinn, N. D. Wagner-Johnston, et al. 2014. Idolalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 123:3390–3397.

26. Wickremasinghe, R. G., A. G. Prentice, and A. J. Steele. 2011. aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells:
clues to the identification of novel therapeutic targets. Br. J. Haematol. 153:545–556.
27. Efremov, D. G., S. Gobessi, and P. G. Longo. 2007. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun. Rev. 7:102–108.
28. Lobert, V. H., A. Brech, N. M. Pedersen, J. Wesche, A. Oppelt, L. Malerød, et al. 2010. Ubiquitination of alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of fibronectin-integrin complexes. Dev. Cell 19:148–159.
29. Paul, N. R., G. Jacquemet, and P. T. Caswell. 2015. Endocytic Trafficking of Integrins in Cell Migration. Curr. Biol. 25:R1092–R1105.
30. Roberts, M., S. Barry, A. Woods, P. van der Sluijs, and J. Norman. 2001. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11:1392–1402.
31. Danen, E. H., and K. M. Yamada. 2001. Fibronectin, integrins, and growth control. J. Cell. Physiol. 189:1–13.
32. Tanaka, H., and S. Nakashima. 2012. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int. J. Hematol. 96:308–319.
33. Blake, S. J., A. Bruce Lyons, C. K. Fraser, J. D. Hayball, and T. P. Hughes. 2008. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 111:4415–4416.
34. Blake, S., T. P. Hughes, G. Mayrhofer, and A. B. Lyons. 2008. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol. 127:330–339.
35. Fei, F., Y. Yu, A. Schmitt, M. T. Rojewski, B. Chen, J. Greiner, et al. 2008. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp. Hematol. 36:1297–1308.
36. Hassold, N., K. Seystahl, K. Kempf, D. Urlaub, M. Zekl, H. Einsele, et al. 2012. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int. J. Cancer 131:E916–E927.